Prostatype Genomics Valuation
Prostatype Genomics seems to be fairly valued based on Macroaxis valuation methodology. Our model determines the value of Prostatype Genomics from analyzing the company fundamentals such as Return On Equity of -0.7, shares owned by insiders of 1.00 %, and Current Valuation of 20.62 M as well as examining its technical indicators and probability of bankruptcy.
Prostatype Genomics Total Value Analysis
Prostatype Genomics AB is at this time estimated to have takeover price of 20.62 M with market capitalization of 42.29 M, debt of 866.67 K, and cash on hands of 7.66 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Prostatype Genomics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
20.62 M | 42.29 M | 866.67 K | 7.66 M |
Prostatype Genomics Investor Information
About 13.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Prostatype Genomics recorded a loss per share of 1.22. The entity had not issued any dividends in recent years. The firm had 1000:1 split on the 31st of October 2024. Based on the key indicators related to Prostatype Genomics' liquidity, profitability, solvency, and operating efficiency, Prostatype Genomics AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in May.Prostatype Genomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Prostatype Genomics has an asset utilization ratio of 0.0249 percent. This suggests that the Company is making kr2.49E-4 for each dollar of assets. An increasing asset utilization means that Prostatype Genomics AB is more efficient with each dollar of assets it utilizes for everyday operations.Prostatype Genomics Ownership Allocation
Prostatype Genomics owns a total of 22.86 Million outstanding shares. Roughly 85.53 pct. of Prostatype Genomics outstanding shares are held by general public with 1.0 % owned by insiders and only 13.47 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Prostatype Genomics Profitability Analysis
The company reported the revenue of 10 K. Net Loss for the year was (15.63 M) with loss before overhead, payroll, taxes, and interest of (5.98 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Prostatype Genomics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Prostatype Genomics and how it compares across the competition.
Complementary Tools for Prostatype Stock analysis
When running Prostatype Genomics' price analysis, check to measure Prostatype Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prostatype Genomics is operating at the current time. Most of Prostatype Genomics' value examination focuses on studying past and present price action to predict the probability of Prostatype Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prostatype Genomics' price. Additionally, you may evaluate how the addition of Prostatype Genomics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |